{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-004189","form_type":"8-K","ticker":"SLDB","cik":"0001707502","company_name":"Solid Biosciences Inc.","filed_at":"2023-01-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:46.218065+00:00","generated_at":"2026-06-20T18:00:43.087099+00:00","sec_items":["2.02","5.02","7.01","8.01","9.01"],"event_type":"leadership","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Solid Biosciences appoints Kevin Tan CFO, discloses $214M cash, targets SGT-003 IND in H2 2023","bullets":["Kevin Tan appointed CFO effective Jan 9, 2023; base salary $425k, 40% bonus target, equity grants.","Preliminary cash and investments $214M as of Dec 31, 2022 (unaudited).","Company anticipates submitting IND for SGT-003 in H2 2023 with patient dosing in late 2023.","Tan previously served as CFO of Selecta Biosciences and Treasurer at Sarepta Therapeutics."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-004189","json":"https://secwatch.observer/filing/0001193125-23-004189.json","markdown":"https://secwatch.observer/filing/0001193125-23-004189.md","text":"https://secwatch.observer/filing/0001193125-23-004189.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1707502/000119312523004189/0001193125-23-004189-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1707502/000119312523004189/d426001d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-20T18:00:43.087099+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"29e9a38cf8","claim":"Kevin Tan was appointed as Chief Financial Officer at Solid Biosciences Inc..","evidence_excerpt":"On January 6, 2023, the Company’s Board of Directors (the “Board”) appointed Kevin Tan as the Company’s Chief Financial Officer, effective as of January 9, 2023","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1707502/000119312523004189/0001193125-23-004189-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Financial Officer"}],"fact_type":"executive_change"},{"claim_id":"a38d186ef2","claim":"Stephen DiPalma departed as Interim Chief Financial Officer at Solid Biosciences Inc..","evidence_excerpt":"In connection with Mr. Tan’s appointment, Stephen DiPalma, the Company’s Interim Chief Financial Officer and principal financial officer and principal accounting officer, will cease to serve in such roles, effective as of the Appointment Date.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1707502/000119312523004189/0001193125-23-004189-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"ceased to serve"},{"label":"Role","value":"Interim Chief Financial Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}